Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRx0518 with Hypofractionated Radiation for Resectable Pancreatic Cancer
NCT04193904Phase 1Terminated
- Sponsor
- 4D Pharma plc
- Start
- Dec 2019
- Primary completion
- May 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MRx0518 in pancreatic adenocarcinoma (PDAC), sponsored by 4D Pharma plc. Primary endpoint: Adverse Events. Started Dec 2019; status: terminated.
02
Drugs
MRx0518
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04193904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193904.